Cardiovascular Diseases Clinical Trial
— HD-REMODELOfficial title:
HaemoDialysis Interventions to REduce Multi-Organ Dysfunction and Effect on Quality of Life (HD-REMODEL) Assessed by MRI Scanning
Verified date | January 2021 |
Source | Fresenius Medical Care Deutschland GmbH |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The purpose of this study is to characterise in detail cardiac, cerebral and renal structure, function and perfusion in patients on haemodialysis (HD) using magnetic imaging techniques. The effects of a standard prescription haemodialysis (dialysate temperature 37 C) will be compared to a thermocontrolled (or isothermic) haemodialysis prescription to ascertain if thermocontrolled HD provides a protective effect on organ perfusion and circulatory stress when compared to conventional haemodialysis. The BTM (blood temperature monitor, Fresenius) offers a way to overcome this to regulate thermal balance during dialysis and achieve a neutral thermal balance (isothermic) over the dialysis session. Other dialysis parameters will be standardised between treatment arms using blood volume monitoring (BVM) and clinical assessments.
Status | Completed |
Enrollment | 17 |
Est. completion date | August 20, 2020 |
Est. primary completion date | May 25, 2019 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 80 Years |
Eligibility | Exclusion Criteria: - Change in dry weight (clinically defined) in 4 weeks prior to recruitment - Dialysate composition other than: sodium=137mmol/L, potassium=2.0mmol/L, calcium=1.5mmol/L, magnesium=0.5mmol/L, glucose 1.0g/L - Instability on dialysis in 4 weeks prior to recruitment leading to either: - Emergency medical attention - Infusion of additional fluid - Loss in consciousness - Arrhythmia - Chest pain - Or any other medical condition that precludes the scan session in opinion of the investigator - Dialysed via a synthetic line, central venous catheter or graft - Qa < 500ml/min - NYHA Stage IV heart failure (New York Heart Association) - Active infection or malignancy - Contraindication to MRI scanning including claustrophobia, pacemaker, metallic implants etc - Pregnancy (pregnancy test will be conducted with female patients aged = 55 years) or planning pregnancy or lactation period - Medical conditions or overall physical frailty precludes scan session in opinion of investigator - Unable or unwilling to provide informed consent - Any condition which could interfere with the patient's ability to comply with the study - Participation in an interventional clinical study during the preceding 30 days Inclusion Criteria: - Age 18-80, male and female - Informed consent signed and dated by study patient and investigator/authorised physician - Average (4 weeks prior to recruitment) Ultrafiltration volumes = 0.5 litres/ dialysis session - Receiving dialysis via an arteriovenous fistula - Must be able to follow simple instruction in English (on safety grounds for MRI scans) and be able to understand the nature and requirements of the study - Stable dialysis prescription - CKD5 (Chronic kidney disease) patients having renal replacement therapy with haemodialysis/ haemodiafiltration (>90 days) |
Country | Name | City | State |
---|---|---|---|
United Kingdom | University of Nottingham, Division of Medical Sciences and Graduate Entry Medicine | Nottingham |
Lead Sponsor | Collaborator |
---|---|
Fresenius Medical Care Deutschland GmbH |
United Kingdom,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Change in cardiac output during standard HD and thermocontrolled HD | Change in cardiac output during standard HD and thermocontrolled HD using Phase Contrast Magnetic Resonance Imaging (PC-MRI) | after 2 and 4 weeks after randomisation | |
Primary | Change in renal perfusion during standard HD and thermocontrolled HD | Change in renal perfusion using Arterial Spin Labelling (ASL) and renal artery flow using PC-MRI | after 2 and 4 weeks after randomisation | |
Primary | Change in cerebral perfusion during standard HD and thermocontrolled HD | Change in cerebral perfusion during standard HD and thermocontrolled HD using ASL | after 2 and 4 weeks after randomisation |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05650307 -
CV Imaging of Metabolic Interventions
|
||
Recruiting |
NCT05654272 -
Development of CIRC Technologies
|
||
Recruiting |
NCT04515303 -
Digital Intervention Participation in DASH
|
||
Completed |
NCT04056208 -
Pistachios Blood Sugar Control, Heart and Gut Health
|
Phase 2 | |
Recruiting |
NCT04417387 -
The Genetics and Vascular Health Check Study (GENVASC) Aims to Help Determine Whether Gathering Genetic Information Can Improve the Prediction of Risk of Coronary Artery Disease (CAD)
|
||
Not yet recruiting |
NCT06211361 -
Cardiac Rehabilitation Program in Patients With Cardiovascular Disease
|
N/A | |
Not yet recruiting |
NCT06032572 -
Evaluation of the Safety and Effectiveness of the VRS100 System in PCI (ESSENCE)
|
N/A | |
Recruiting |
NCT04514445 -
The BRAVE Study- The Identification of Genetic Variants Associated With Bicuspid Aortic Valve Using a Combination of Case-control and Family-based Approaches.
|
||
Enrolling by invitation |
NCT04253054 -
Chinese Multi-provincial Cohort Study-Beijing Project
|
||
Completed |
NCT03273972 -
INvestigating the Lowest Threshold of Vascular bENefits From LDL Lowering With a PCSK9 InhibiTor in healthY Volunteers
|
N/A | |
Completed |
NCT03680638 -
The Effect of Antioxidants on Skin Blood Flow During Local Heating
|
Phase 1 | |
Recruiting |
NCT04843891 -
Evaluation of PET Probe [64]Cu-Macrin in Cardiovascular Disease, Cancer and Sarcoidosis.
|
Phase 1 | |
Completed |
NCT04083846 -
Clinical Study to Investigate the Pharmacokinetic Profiles and Safety of High-dose CKD-385 in Healthy Volunteers(Fed)
|
Phase 1 | |
Completed |
NCT04083872 -
Clinical Study to Investigate the Pharmacokinetic Profiles and Safety of Highdose CKD-385 in Healthy Volunteers(Fasting)
|
Phase 1 | |
Completed |
NCT03693365 -
Fluid Responsiveness Tested by the Effective Pulmonary Blood Flow During a Positive End-expiratory Trial
|
||
Completed |
NCT03619148 -
The Incidence of Respiratory Symptoms Associated With the Use of HFNO
|
N/A | |
Completed |
NCT03466333 -
Postnatal Enalapril to Improve Cardiovascular fUnction Following Preterm Pre-eclampsia
|
Phase 2 | |
Completed |
NCT04082585 -
Total Health Improvement Program Research Project
|
||
Completed |
NCT05132998 -
Impact of a Comprehensive Cardiac Rehabilitation Program Framework Among High Cardiovascular Risk Cancer Survivors
|
N/A | |
Completed |
NCT05067114 -
Solutions for Atrial Fibrillation Edvocacy (SAFE)
|